

Clinical Policy: Biofeedback

Reference Number: CP.MP.168

Date of Last Revision: 11/25

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Biofeedback therapy provides visual, auditory or other evidence of the status of certain body functions so that a person can exert voluntary control over the functions, and thereby alleviate an abnormal bodily condition. Biofeedback therapy often uses electrical devices to transform bodily signals indicative of such functions as heart rate, blood pressure, skin temperature, salivation, peripheral vasomotor activity, and gross muscle tone into a tone or light, the loudness or brightness of which shows the extent of activity in the function being measured.¹

Note: For biofeedback for behavioral health conditions, refer to *CP.BH.300 Biofeedback for Behavioral Health Disorders*.

Policy/Criteria

- I. It is the policy of health plans affiliated with Centene Corporation® that biofeedback is **medically necessary** when all of the following are met:
 - A. Member/enrollee is cognitively and physically capable of participating in the agreed upon plan of care and motivated to actively participate in the treatment plan requirements (e.g., practice and follow-through at home);

Note: If member/enrollee is a child, support and guidance are available for fulfillment of the plan of care (e.g., practice and follow-through at home);
 - B. One of the following:
 1. Urinary incontinence (i.e., stress, urge, or mixed) in adult members/enrollees who have failed a documented four week trial of pelvic muscle exercise training;
 2. Dysfunctional voiding in children when other alternative options have been unsuccessful (e.g., timed voiding, prophylactic antibacterial therapy for recurrent urinary tract infections, short term anticholinergic medications to assist developing a normal voiding pattern);
 3. Fecal incontinence and all of the following:
 - a. One of the following:
 - i. Anorectal manometry demonstrates weakness of the external anal sphincter;
 - ii. Decreased ability to perceive rectal distension because of nerve injury;
 - b. None of the following contraindications:
 - i. Isolated internal anal sphincter weakness;
 - ii. Overflow incontinence associated with behavioral or psychiatric disorders;
 - iii. Neurological disorders associated with substantial loss of rectal sensation and/or the inability to contract the external anal sphincter;
 - iv. Decreased rectal storage capacity from resection, inflammation, or fibrosis;
 - v. Suspected or established major structural damage to continence mechanisms;
 4. Chronic constipation with dyssynergic defecation;
 5. Tension or migraine headaches;
 6. Chronic pain;

7. Muscle re-education of specific muscle groups or for treating pathological muscle abnormalities of spasticity, incapacitating muscle spasm (including pain due to spasm), or weakness.

II. It is the policy of health plans affiliated with Centene Corporation that there is insufficient evidence to support the safety and efficacy of biofeedback for any other conditions than those specified above.

Background

Biofeedback therapy provides visual, auditory or other evidence of the status of certain body functions to allow an individual to exert voluntary control over the functions, and thereby alleviate an abnormal bodily condition. Biofeedback therapy often uses electrical devices to transform bodily signals indicative of such functions as heart rate, blood pressure, skin temperature, salivation, peripheral vasomotor activity, and gross muscle tone into a tone or light, the loudness or brightness of which shows the extent of activity in the function being measured.¹⁷

First line treatment of urinary incontinence (i.e., stress, urgency, mixed) consists of behavioral treatments with an emphasis on improving quality of life. Initial treatment includes lifestyle modifications and pelvic floor muscle exercise. Biofeedback is used as an adjunct to pelvic floor muscle exercises. By providing individuals with concurrent feedback on muscle tone, biofeedback is intended to improve the patient's ability to perform pelvic muscle exercises. Augmented versions also use abdominal and perineal EMG recordings to demonstrate improper contraction of abdominal and gluteal muscles. A systematic review and meta-analysis of 17 randomized or quasi-randomized trials found that compared with women who received pelvic floor muscle exercises alone, those that also received biofeedback were more likely to report improvement or cure of urinary incontinence.¹

Dysfunctional voiding in children is a learned behavior of abnormal urination, which often evolves from attempts to suppress impending or active bladder contractions by inappropriately contracting the pelvic floor muscles, thereby tightening the urinary sphincter complex. Symptoms vary, but daytime wetness and urinary tract infections are common.³ Other urinary symptoms include urgency, frequency, infrequency, and constipation. Usual care of dysfunctional voiding includes voiding on a schedule and keeping voiding diaries. Pelvic floor exercises may help children gain conscious control of pelvic floor musculature and urination.⁴ Biofeedback teaches children how to identify and control the muscle groups involved in voiding. It is reserved for children with dysfunctional voiding despite an adequate trial of conservative therapy and/or pharmacotherapy. Available studies suggest that biofeedback-directed pelvic floor exercises can improve urinary function in dysfunctional voiding, including those who have previously failed conservative treatment. Biofeedback therapy may result in a faster resolution of symptoms than traditional pelvic floor training without biofeedback.²

Biofeedback therapy improves symptoms in more than 70% of patients with defecatory disorders. Biofeedback can be useful in the treatment of constipation to train patients to relax their pelvic floor muscles during straining and to correlate relaxation and pushing to achieve defecation. By the relearning process, the non-relaxing pelvic floor is gradually suppressed and normal coordination restored. Biofeedback has been shown to improve rectoanal coordination

during defecation and symptoms of constipation despite reduced laxative use. Biofeedback is also used in the treatment of fecal incontinence.⁴

American Gastroenterological Association (AGA)

The AGA states that pelvic floor retraining by biofeedback therapy rather than laxatives is recommended for defecatory disorders (strong recommendation, high-quality evidence).³ Instrumented anorectal biofeedback therapy should be used to manage symptoms in defacatory disorders (strong recommendation; minimal risk of harm; quality of evidence: moderate).⁵

American Society of Colon and Rectal Surgeons (ASCRS)

The 2023 updated ASCRS clinical practice guidelines for the management of fecal incontinence state that biofeedback may be considered for patients with fecal incontinence (conditional recommendation; quality of evidence: low). The guidelines state that biofeedback is a noninvasive option for patients with fecal incontinence “who have not responded adequately to other conservative measures. The updated guidelines report that nonrandomized, prospective and retrospective studies show 64% to 89% improvement in fecal incontinence with biofeedback, but there are methodological weaknesses with a number of the smaller studies. These study weaknesses, along with randomized controlled trials comparing biofeedback to other treatment options but not to sham therapy, make it difficult to determine a definitive conclusion on the utility of biofeedback. The ASCRS states that in order to determine the efficacy of biofeedback for fecal incontinence, larger, well-designed studies are needed.³

Coding Implications

This clinical policy references Current Procedural Terminology (CPT[®]). CPT[®] is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2023, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT [®] Codes	Description
90901	Biofeedback training by any modality
90912	Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed; initial 15 minutes of one-on-one physician or other qualified health care professional contact with the patient
90913	Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed; each additional 15 minutes of one-on-one physician or other qualified health care professional contact with the patient (List separately in addition to code for primary procedure)

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Policy adopted from Health Net NMP168 Biofeedback	06/17	07/17

Reviews, Revisions, and Approvals	Revision Date	Approval Date
References reviewed and updated. Removed CPT 90911 – code deleted 1/1/2020. Replaced with 2020 CPT codes, 90912 and 90913. Removed I.B.5 “Anal muscle abnormalities of spasticity, incapacitating muscle spasm, and/or muscle weakness” as duplicative and revised language in I.B.3. Added contraindications to I.B.3.b.	04/20	05/20
References reviewed and updated. In II, replaced “experimental /investigational” language with the statement that there is insufficient evidence to draw conclusions regarding the efficacy of biofeedback for any other circumstances than those specified above.” Replaced “member” with “member/enrollee.”	05/21	05/21
Added note to refer to CP.BH.300 Neurofeedback for behavioral health conditions.	10/21	
Annual review. Updated background with no impact on criteria. Changed “review date” in the header to “date of last revision” and “date” in the revision log header to “revision date.” References reviewed, updated and reformatted. Reviewed by specialist.	12/21	12/21
Annual review. References reviewed and updated. In I.B.1. changed “female” to “members/enrollees who have or previously had a female reproductive system” and reworded “cognitively intact” to “no cognitive impairments that would limit participation”. ICD-10 code table removed.	11/22	11/22
Annual review. Minor rewording in Criteria I.B.1. Background updated to reflect 2023 updated clinical practice guidelines from the American Society of Colon and Rectal Surgeons with no impact on criteria. References reviewed and updated. Fecal incontinence criteria reviewed by internal specialist. Policy reviewed by external specialist.	11/23	11/23
Annual review. Reworded Criteria I. for clarity and removed statement in Criteria I. regarding reconsideration of medical necessity if more than 14 biofeedback treatment sessions in a 12-month period. Reworded Criteria I.A. for clarity and removed criterion regarding individual being capable of participating in treatment plan and incorporated this into Criteria I.A. Removed criterion requiring a readily identifiable and measurable response and criterion regarding qualified practitioners who can perform biofeedback training. Reworded Criteria I.B. for clarity. Removed gender specific verbiage, no cognitive impairments, and Kegel exercise verbiage in Criteria I.B.1. Updated Criteria I.B.4. to only state “chronic constipation” for clarity. Updated Criteria I.B.5. to only state “tension or migraine headaches” for clarity. Removed verbiage regarding a rehabilitation program in Criteria I.B.6. for chronic pain. Removed verbiage regarding more conventional treatments being unsuccessful in Criteria I.B.7. for clarity. Reworded Criteria II. for clarity with no impact to criteria. Background updated with no impact on criteria. References reviewed and updated. Reviewed by external specialist.	11/24	11/24
Annual review. Updated title of CP.BH.300 in the Note. Added “with dyssynergic defecation” to I.B.4. References reviewed and updated.	11/25	11/25

References

1. Fernandes ACN, Jorge CH, Weatherall M, Ribeiro IV, Wallace SA, Hay-Smith EJC. Pelvic floor muscle training with feedback or biofeedback for urinary incontinence in women. *Cochrane Database Syst Rev*. 2025;3(3):CD009252. Published 2025 Mar 11. doi:10.1002/14651858.CD009252.pub2
2. Nepple KG, Cooper CS. Management of bladder dysfunction in children. UpToDate. www.uptodate.com. Published January 22, 2024. Accessed October 28, 2025.
3. American Gastroenterological Association, Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. *Gastroenterology*. 2013;144(1):211 to 217. doi:10.1053/j.gastro.2012.10.029
4. Bordeianou LG, Thorsen AJ, Keller DS, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Fecal Incontinence. *Dis Colon Rectum*. 2023;66(5):647-661. doi:10.1097/DCR.0000000000002776
5. Wald A, Bharucha AE, Limketkai B, et al. ACG Clinical Guidelines: Management of Benign Anorectal Disorders. *Am J Gastroenterol*. 2021;116(10):1987-2008. doi:10.14309/ajg.0000000000001507
6. Bertotto A, Schvartzman R, Uchôa S, Wender MCO. Effect of electromyographic biofeedback as an add-on to pelvic floor muscle exercises on neuromuscular outcomes and quality of life in postmenopausal women with stress urinary incontinence: A randomized controlled trial. *Neurourol Urodyn*. 2017;36(8):2142 to 2147. doi:10.1002/nau.23258
7. Fitz FF, Resende AP, Stüpp L, Sartori MG, Girão MJ, Castro RA. Biofeedback for the treatment of female pelvic floor muscle dysfunction: a systematic review and meta-analysis. *Int Urogynecol J*. 2012;23(11):1495 to 1516. doi:10.1007/s00192-012-1707-1
8. Tugtepe H, Thomas DT, Ergun R, et al. Comparison of biofeedback therapy in children with treatment-refractory dysfunctional voiding and overactive bladder. *Urology*. 2015;85(4):900 to 904. doi:10.1016/j.urology.2014.12.031
9. Krzemińska K, Maternik M, Drożyńska-Duklas M, et al. High efficacy of biofeedback therapy for treatment of dysfunctional voiding in children. *Cent European J Urol*. 2012;65(4):212 to 215. doi:10.5173/cej.2012.04.art6
10. Kajbafzadeh AM, Sharifi-Rad L, Ghahestani SM, Ahmadi H, Kajbafzadeh M, Mahboubi AH. Animated biofeedback: an ideal treatment for children with dysfunctional elimination syndrome. *J Urol*. 2011;186(6):2379 to 2384. doi:10.1016/j.juro.2011.07.118
11. Desantis DJ, Leonard MP, Preston MA, Barrowman NJ, Guerra LA. Effectiveness of biofeedback for dysfunctional elimination syndrome in pediatrics: a systematic review. *J Pediatr Urol*. 2011;7(3):342 to 348. doi:10.1016/j.jpuro.2011.02.019
12. Robson KM, Lembo AJ. Fecal incontinence in adults: Management. UpToDate. www.uptodate.com. Published September 24, 2025. Accessed October 29, 2025.
13. MacIntosh A, Lam E, Vigneron V, Vignais N, Biddiss E. Biofeedback interventions for individuals with cerebral palsy: a systematic review. *Disabil Rehabil*. 2019;41(20):2369 to 2391. doi:10.1080/09638288.2018.1468933
14. Dinces EA. Treatment of tinnitus. UpToDate. www.uptodate.com. Published July 15, 2025. Accessed October 29, 2025.
15. Bharucha AE, Rao SSC, Shin AS. Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders. *Clin Gastroenterol Hepatol*. 2017;15(12):1844 to 1854. doi:10.1016/j.cgh.2017.08.023

16. Hirakawa T, Suzuki S, Kato K, Gotoh M, Yoshikawa Y. Randomized controlled trial of pelvic floor muscle training with or without biofeedback for urinary incontinence. *Int Urogynecol J*. 2013;24(8):1347 to 1354. doi:10.1007/s00192-012-2012-8
17. National coverage determination: biofeedback therapy (30.1). Centers for Medicare and Medicaid Services Web site. <http://www.cms.hhs.gov/mcd/search.asp>. Accessed October 30, 2025.
18. Clemens JQ. Urinary incontinence in males. UpToDate. www.uptodate.com. Published July 10, 2025. Accessed October 29, 2025.
19. Comiter CV, Speed J. Urinary incontinence after prostate treatment. UpToDate. www.uptodate.com. Published May 16, 2024. Accessed October 29, 2025.
20. National coverage determination: biofeedback therapy for the treatment of urinary incontinence (30.1.1). Centers for Medicare and Medicaid Services Web site. <http://www.cms.hhs.gov/mcd/search.asp>. Published July 01, 2001. Accessed October 30, 2025.
21. Taylor FR. Tension-type headache in adults: Preventative treatment. UpToDate. www.uptodate.com. Published July 01, 2024. Accessed October 29, 2025.
22. Busse JW, Casassus R, Carrasco-Labra A, et al. Management of chronic pain associated with temporomandibular disorders: a clinical practice guideline. *BMJ*. 2023;383:e076227. Published 2023 Dec 15. doi:10.1136/bmj-2023-076227
23. American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. *Anesthesiology*. 2010;112(4):810-833. doi:10.1097/ALN.0b013e3181c43103

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of member/enrollees. This clinical policy is not intended to recommend treatment for member/enrollees. Member/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, member/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, member/enrollees and their representatives agree to be bound by such terms and conditions by providing services to member/enrollees and/or submitting claims for payment for such services.

Note: For Medicaid member/enrollees, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare member/enrollees, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.